Intermediate-risk group in patients with transitional cell carcinoma of the bladder: Prediction of high-risk patients in this heterogeneous group

Urologia Internationalis

Volumn 83, Issue 3, 2009, Pages 295-299

  Yencilek, F ^a,c   Onal, B ^b   Erozenci, A ^b   Talat, Z ^b   Ataus, S ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Control cystoscopy; Intermediate risk; Management; Recurrence rate; Transitional cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; CANCER RECURRENCE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 70350348314     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000241671     Document Type: Article

References (16)

1. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C; European Association of Urology (EAU) Working Group on Oncological Urology: Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112.
2. Huncharek M, Kupelnick B: Impact of Intravesical chemotherapy versus BCG immunotherapy on recurrences of superficial tran- sitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 2003; 26: 402-407.
3. Oge O, Erdem E, Atsü N, Sahin A, Ozen H: Proposal for changes in cystoscopic followup of patients with low-grade pTa bladder tumor. Eur Urol 2000; 37: 271-274.
4. Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F, Lusuardi L, Pa- lermo S, Mian C: Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004; 63: 472-475.
5. Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumors. Geneva, WHO, 1973.
6. Millán-Rodríguez F, Ghéchile-Toniolo G, Salvador-Bayarri J, et al.: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-684.
7. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth KH: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477.
8. Fitzpatrick JM, West AB, Butler MR, et al.: Superficial bladder tumors (stage pTa, grade 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986; 135: 920-922.
9. Holmäng S, Hedelin H, Anderström C, et al.: Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999; 162: 702-707.
10. Andius P, Holmäng S: Bacillus Calmette- Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004; 93: 980-984.
11. Chopin DK, Gattegno B: Superficial bladder tumors. Eur Urol 2002; 42: 533-541.
12. Kurth K, Denis L, Bouffioux C, et al.: Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995; 31: 1840-1846.
13. Parmar MKB, Freedman LS, Hargreave TB, et al.: Prognostic factors for recurrence and follow up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-288.
14. Hisataki T, Miyao N, Masumori N, et al.: Risk factors for multiple intravesical recurrences of superficial bladder cancer. Urology 2001; 58: 935-939.
15. Solsona E, Iborra I, Dumont R, et al.: The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164: 685-689.
16. Lockyer CR, Sedgwick JE, Gillatt DA: Beware the BCG failures: a review of one institution's results. Eur Urol 2002; 42: 542-546.